Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

NCT07508306 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Sentinel Lymph Node Biopsy (SLNB)
Early Stage Ovarian Tumors

Interventions

PROCEDURE: Sentinel node biopsy with patent blue dye

Sponsor

Faculty of Medicine of Tunis